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Abstract
Background: Neonatal hepatitis refers to a heterogeneous group of disorders, caused by many
factors including cytomegalovirus infection, revealing similar morphologic changes in the liver of an
infant less than 3 months of age. Approximately 40% of cholestasis in infants is due to neonatal
hepatitis. It may cause latent or acute cholestatic or chronic hepatitis, including cirrhosis in
immunocompetant infant.
Methods: Twelve infants diagnosed with neonatal cytomegalovirus hepatitis in the last one year
were included in the study. Group 1 consisted of seven babies treated with ganciclovir for 21 days.
Group 2 included five cases who did not receive antiviral treatment. Physical examination,
biochemical, serologic and virologic tests were done for both groups at the time of diagnosis and
in the third month.
Results: Initial levels of total bilirubin, aminotransferases, gamma glutamyl transpeptidase, and
alkaline phosphatase revealed a significant decrease after the treatment in Group 1 (p < 0.05) when
compared with Group 2. This study revealed that ganciclovir treatment is a safe and effective in
cases with cholestatic hepatitis. Similarly, all the patients in the treatment group had evidence of
improvement serologically and virologically, while the comparison group did not reveal any
significant change(p < 0.01).
Conclusion: The clinical spectrum of perinatal infection varies from an asymptomatic infection or
a mild disease to a severe systemic involvement, including central nervous system. The treatment
in the early period of infection improved serologic markers and cholestatic parameters significantly.
Further studies will lead us to clarify the efficacy of ganciclovir treatment in the early period of
cytomegalovirus hepatitis, and the preventive role of anti-viral therapy on progressive liver disease
due to cholestasis and hepatitis in neonatal cytomegalovirus infection.
Background
Neonatal hepatitis is a specific type of hepatitis seen in the
first months of life. Hepatitis A-E viruses and other hepa-
totrophic viruses (Epstein-Barr virus(EBV), herpes viruses,
adenoviruses and parvovirus) are known to be the main
causes of the disease. It is obvious that A-E hepatotrophic
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viruses are the main causes of etiology in 10% of acute
viral hepatitis cases without immunosuppression.
Cytomegalovirus (CMV) is a member of herpes virus fam-
ily, and although it is known that CMV and other herpes
viruses can cause significant pathologies (particularly in
immunodeficient patients), they can also affect individu-
als with normal immune system. Typical acute unicteric
hepatitis, as a part of systemic infection, is one of these
pathologies [1].
Approximately 20% of children less than 15 years of age
and 50–60% of individuals younger than 25–30 years of
age are infected with CMV. It is known that virus replicates
in both hepatocytes and cholangiocytes during infection.
However, controversy exists about the pathogenesis of
hepatic disease whether related to the direct cytopathic
effect of the virus or the immune response of the host. In
addition, the hepatocyte damage in latent infections has
not yet been well explained. Besides this, it is obvious that
patients with chronic viral hepatitis and cirrhosis may
have more sensitivity to acute CMV infections resulting in
additional hepatic damage[2-4].
In severe cases, ganciclovir or foscarnet treatment may be
effective. Although ganciclovir treatment reported to be
effective in CMV retinitis, esophagitis, hepatitis and pneu-
monia in adults, there is insufficient research in children.
It is mentioned that ganciclovir may be used effectively in
symptomatic congenital or neonatal CMV infections but
its side effects are of concern [3].
In the current study, the objective was to evaluate efficacy
of ganciclovir in cholestasis of neonatal CMV hepatitis,
which is an important step for prevention of chronic CMV
hepatitis.
Methods
Twelve infants diagnosed with neonatal cytomegalovirus
hepatitis in the last one year were included in the study.
Local ethics comittee (Abant Izzet Baysal University,
Duzce Medical Faculty Ethics Committee) approved the
study and the written informed consent obtained from
the parents of the patients. The babies (n:7) whose par-
ents accepted ganciclovir therapy formed the treatment
group(Group1), while the other five babies without gan-
ciclovir therapy formed the comparison group (Group2)
(Table 1). One baby with ileal atresia (because he may
have additional enterohepatic circulation disorder) and
another one with myoclonic convulsions receiving anti-
convulsant therapy (because he may have additional toxic
hepatitis) were excluded before the study groups were
chosen. Liver biopsy was performed in babies with unex-
plained hypertransaminasemia, icterus and/or hepatome-
galy, in order to reveal idiopathic neonatal hepatitis,
extrahepatic bilier atresia, immune insufficiency and met-
abolic hepatic disorders (such as α1antityripsine defi-
ciency, storage disorders) which were also among
exclusion criteria. Convulsions, petechia, purpura, chori-
oretinitis, microcephaly, neuromuscular dysfunction, cer-
ebral calcifications, and/or severe disease that may be seen
in congenital CMV infections were not observed in any
patient.
Children in Group 1 were treated with ganciclovir (10 mg/
kg/day, in two doses) for 21 days. Antipruritic treatment
for cholestasis, calcium, vitamin D, and other lipophilic
vitamin supplementation were given to both groups.
All the patients' clinical and laboratory parameters (age,
icterus, organomegaly, ALT, AST, ALP, GGT, T. Bil., D. Bil.,
CMV Ig G and CMV Ig M antibody, CMV avidity and
CMV-DNA) were evaluated initially and at the third
month of the study. Anti-CMV IgG and IgM ab titers were
measured with ELISA method and CMV-DNA was
detected with PCR. CMV-DNA was purified with QIAmp
DNA Blood Mini Kit (QIAGEN, Hamburg). Quantitative
PCR analyses was performed by RealArt™ CMV RG PCR
Kit used with Rotor-Gene™ 2000/3000. The quantitation
standards were defined as copies/µl. An equation was
Table 1: The Demographic Characteristics of the Groups
Groups
(n = number of cases)
Age (months)
Mean ± SD
 Median
Sex Weight (kg)
Mean ± SD
 Median
MF
Group 1 (n = 7) *3.7 ± 2.4
3
** 3 4  5.05 ± 1.6
4.7
Group 2 (n = 5) *6.6 ± 2.2
7
** 4 1  5.97 ± 2
5.9
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used to convert the values determined using the standard
curve into copies/ml of sample material:
For preparation of PCR assay, a standard volume (20 µl),
of sample DNA was mixed with 30 µl of CMV RG Master.
Data analyses was performed with Rotor-Gene™ software
according to the manufacturer's manual.
Statistical analysis was performed using Mann-Whitney U
Test for comparison of the initial and the third month
changes of weight and CMV-DNA PCR, Fisher's Chi
square exact test for the variants such as sex, organomeg-
aly, jaundice and CMV antibody titers, and Wilcoxon Test
was used for the comparison of individuals among each
group (SPSS 13.0 version).
Results
The mean age of seven babies (four female, three male) in
Group 1 and five babies (one female, four male) in Group
2 was 3.7 ± 2.4 months and 6.6. ± 2.2 months, respec-
tively. One baby in Group 1 and two babies in Group 2
had low weight percentile at the initial evaluation. There
were no significant statistical difference between groups
regarding to age, sex and weight (NS, NS, NS respectively).
In the physical examination, five babies in Group 1 and
two in Group 2 had hepatomegaly (liver was palpated >2
cm below the last rib) at the first evaluation (NS). One
baby in each group had palpable spleen evaluated as a
normal variation.
Liver biopsy was performed for 7/7 babies in Group 1 and
for 4/5 babies in Group 2. Although hepatic inclusion
bodies are rarely found in the histopathologic examina-
tion of pediatric cases, it was detected in one baby in
Group 1. Granulomatous changes and findings related to
cholestasis were determined in four babies in the treat-
ment group and two babies in the comparison group.
Nonspecific histopathological findings of CMV hepatitis
as lymphomonocytic cell infiltration, hydrophic degener-
ation, mild steatosis, perisinusoidal fibrosis, and Kuppfer
cell hyperplasia were found in all babies.
At the initial evaluation, three babies in Group 1 and one
baby in Group 2 had icterus. They were still icteric at the
third month (NS) (Table 2, 3). In comparison with Group
2, initial levels of total bilirubin, AST, ALT, GGT, and ALP
revealed a significant decrease in Group 1 after the treat-
ment(p < 0.05) The differences of initial and third month
values were statistically significant among the babies in
Group 1 (Table 3). No significant change was observed in
the comparison group at the third month regarding to ini-
tial values (NS) (Table 3). The serological evaluation for
CMV revealed that all the babies were CMV IgG (+) and
CMV IgM antibody was found in five and three babies in
the treatment and comparison groups, respectively. CMV
avidity test was not available for the whole group. The
avidity value indicating infection longer than 3 months
(avidity index >0.8) was determined in 60% and 33% of
the evaluated babies in the treatment and the comparison
group, respectively (Table 4). The confirmative serological
changes were defined as the decrease in CMV IgG anti-
body or avidity titers, or loss of CMV-IgM antibody at the
third month's evaluation. While all the patients in the
treatment group had evidence of serologic improvement
(p < 0.01), the comparison group did not reveal any sig-
nificant change (NS). Similarly, CMV-DNA PCR values
decreased to desirable levels following the treatment in
Group 1 (p = 0.05). However, the changes in the compar-
ison group were inconsiderable (Table 4).
Discussion
Neonatal hepatitis refers to a group of pathologies causing
similar morphologic changes in the liver of the babies less
than three months of age. It is blamed for 40% of choles-
tatic situations in the neonates after exclusion of extrahe-
patic biliary atresia. It affects males more frequently than
females, and similar results were found in the present
study. As the term "idiopathic neonatal hepatitis" refers to
the neonatal hepatitis of unknown (but probably multi-
factorial) etiology, "neonatal hepatitis" is caused by a
group of well defined etiologic factors, so treatment
should be considered [1,3,5].
Neonatal cytomegalovirus infection may occur due to
either intrauterine or perinatal exposure to CMV infected
cervicovaginal secretion and breast milk. The clinical spec-
trum of perinatal infection varies from an asymptomatic
Result (copies/ml):
Result (copies/ l)   Elution volume( l) µµ ×
S Sample volume (ml)
Table 2: The Comparison of the Physical Examination Findings of the Groups
Groups Jaundice
(n)
Hepatomegaly
(n)
Group 1 (n = 7) Initial *3 **5
Posttreatment 2 2
Group2 (n = 5) Initial *1 **2
Control 2 2
*, ** NSBMC Gastroenterology 2007, 7:9 http://www.biomedcentral.com/1471-230X/7/9
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infection or a mild disease to severe systemic involve-
ment, including central nervous system [6].
The clinical presentation of acute neonatal CMV infection
resembles the mononucleosis of the Epstein-Barr virus
seen in neonates and immunodeficient individuals with
fever, malaise, and cervical lymphadenopathy. Severe
jaundice and granulomatous hepatitis also have been
established due to neonatal CMV infection [1,3]. Physical
examination may reveal minimal hepatomegaly and mild
jaundice, in addition to slightly increased serum ami-
notranspherases (less than threefold of normal values)[4].
CMV infection is unlikely to be a cause of massive hepato-
cellular necrosis in a normal host. Previous studies
reported that transaminases reached the highest levels
(<200 U) in the second or third week of infection, decreas-
ing to normal values by the fifth week [4]. In our study,
transaminases increased moderately in both groups, but a
significant decrease at the third month was observed only
in the treatment group.
The laboratory tests used for serologic diagnosis of CMV
hepatitis are CMV-IgM ab, CMV early antigen (in tissue or
blood), CMV-DNA PCR and virus cultures [8,12]. We
could not obtain viral cultures or early antigen titers of the
babies in our study, but the liver biopsy evaluations sug-
gested CMV hepatitis. In the histopathologic examination
of liver, the presence of cytomegalic cells and inclusion
bodies refers to the intensive immune activation against
viral attack. The liver damage in an immunocompetant
individual is mostly due to the primary immune response
of the host, whereas cytopathic damage of the virus has
priority in patients suffering from immune deficiency [1].
Chang et al. recently evaluated the existence of CMV-DNA
in liver biopsy samples of healthy neonates in comparison
to the neonates with neonatal hepatitis. He reported that
CMV DNA was detected in 46% of babies with neonatal
hepatitis (n: 50) whereas none of the healthy group had
viral DNA (n: 30). Thus, he suggested that CMV could
play a major role in the pathogenesis of neonatal hepatitis
[9]. Although it has been was reported that hepatomegaly
might regress spontaneously in the first year of life in
babies with congenital CMV infection, portal hyperten-
sion may occur without the evidence of cirrhosis [10,11].
In the current study, one patient in the comparison group
died of abundant upper gastrointestinal haemorrhage at
Table 4: The Comparison of serological CMV markers in Groups
Groups CMV IgM (+) patient
no/total
CMV IgG avidity >0,8 patient
n
* ΨCMV DNA
copy/ml
Group 1 (n = 7) Initial 7/7 5 2230(166–9240)
Posttreatment 0/7 3 14 (8–1930)
Group 2 (n = 5) Initial 3/5 3 2178(158–2917)
Control 3/5 1 1915(656–2900)
 The ratio of patients, in each group, having affirmative results in the second evaluation (p < 0.01)
* Median (minimum-maximum)
Ψ The comparison of value changes between first and second evaluation (p < 0.05)
Table 3: The Comparison of the Biochemical Values of the Groups
Groups T. billirubin 
mean ± sd 
median
D. Billirubin 
mean ± sd 
median
ALT 
mean ± sd 
median
AST 
mean ± sd 
median
ALP 
mean ± sd 
median
GGT 
mean ± sd median
Group 1 n = 7 Initial *4.6 ± 3.2
4.6
*3.9 ± 2.5
4
*119.4 ± 56.4
80
*167 ± 68.4
197
*1148 ± 300
750
 4414 ± 186.3
110
Posttreatment 1.29 ± 0.82
2.5
0.53 ± 0.27
0.3
53 ± 18.5
54
75 ± 28.1
58
556 ± 196.5
324
150.7 ± 61.5
71
Group 2 n = 5 Initial **2.52 ± 1.07
1.45
**1.42 ± 0.45
0.25
**172.7 ± 57.6
92
**155.2 ± 68
93
**393.5 ± 44.7
381
 67.7 ± 25
49
Control 4.37 ± 2.21
0.3
2.97 ± 1.75
0.1
123.2 ± 18.5
98
152.7 ± 47
116.5
435.7 ± 37.5
311
73.2 ± 24.6
51
Comparison of initial and post treatment values among Group 1
 p < 0.01
* p < 0.05
Comparison of initial and control values among Group 2
**,  NSBMC Gastroenterology 2007, 7:9 http://www.biomedcentral.com/1471-230X/7/9
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the age of 18 months as a result of portal hypertension
without cirrhosis. Two patients in the same group also
progressed to chronic hepatitis.
The necessity of treatment is controversial in neonatal
CMV infection, as spontaneous recovery is expected in
most cases unless severe systemic disease occurs [3,12].
However, as in the present study, an increasing number of
studies indicate the necessity of treatment, especially in
cases with symptoms of acute or chronic cholestatic hep-
atitis or proven histopathological findings [3,13-17]. A
new study from Lanari et al. demonstrated the importance
of high CMV-DNA titer on development of sequelaes. Fur-
thermore, they suggested that the CMV-DNA quantity
could be useful for identifying the patients who will ben-
efit highly from antiviral therapy [18].
Ganciclovir is recommended as a first step antiviral agent
for the management of congenital CMV infection. Most
common adverse effects of ganciclovir treatment include
dose-dependent neutropenia and blood counts including
absolute neutrophil count. Therefore, leukocyte counts
should be monitored closely during treatment. In our
treatment group, we have not seen any severe adverse
effects requiring the cessation of the treatment [3,6].
Conclusion
We suggest that ganciclovir therapy significantly improves
the clinical course of neonatal cholestatic CMV hepatitis.
Currently the number of studies of neonatal cholestatic
CMV hepatitis is insufficient. New and extensive research
will lead us to clarify the efficacy of ganciclovir treatment
in the early period of CMV hepatitis, and the preventive
role of anti-viral therapy on progressive liver disease due
to cholestasis and hepatitis in neonatal CMV infection.
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